CAMBRIDGE, Mass. - Alnylam Pharmaceuticals (NASDAQ:ALNY) announced Tuesday partnerships with Viz.ai and the American Heart Association aimed at improving early detection and care coordination for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). The $40.7 billion biotech company has shown strong momentum with 65% revenue growth over the last twelve months.
The company is working with Viz.ai to develop an AI-enabled care pathway designed to help clinicians identify ATTR-CM patients earlier. The collaboration includes the AWARE study, a multi-system prospective implementation study evaluating how AI-enabled screening can be integrated into clinical workflows and its impact on diagnostic timelines and care coordination.